Ad is loading...
JDVRX
Price
$24.97
Change
+$0.26 (+1.05%)
Updated
Nov 22 closing price
VVIAX
Price
$70.26
Change
+$0.54 (+0.77%)
Updated
Nov 22 closing price
Ad is loading...

JDVRX vs VVIAX

Header iconJDVRX vs VVIAX Comparison
Open Charts JDVRX vs VVIAXBanner chart's image
PGIM Jennison Value R
Price$24.97
Change+$0.26 (+1.05%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$70.26
Change+$0.54 (+0.77%)
VolumeN/A
CapitalizationN/A
JDVRX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JDVRX vs. VVIAX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JDVRX is a Buy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. JDVRX (685M). VVIAX pays higher dividends than JDVRX: VVIAX (2.36) vs JDVRX (0.75). JDVRX was incepted earlier than VVIAX: JDVRX (19 years) vs VVIAX (24 years). JDVRX is a more actively managed with annual turnover of: 28.00 vs. VVIAX (10.00). JDVRX has a lower initial minimum investment than VVIAX: JDVRX (0) vs VVIAX (3000). VVIAX annual gain was more profitable for investors over the last year : 26.09 vs. JDVRX (23.98). VVIAX return over 5 years is better than : 53.09 vs. JDVRX (27.53).
JDVRXVVIAXJDVRX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence19 years24 years-
Gain YTD24.04619.672122%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets685M184B0%
Annual Yield % from dividends0.752.3632%
Returns for 1 year23.9826.0992%
Returns for 3 years7.7024.7731%
Returns for 5 years27.5353.0952%
Returns for 10 years14.02112.2612%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics